Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Exact Sciences is changing the way we think about treating cancer and is committed to providing life-changing treatment guidance for patients facing cancer. For decades, cancer treatment was often a one-size-fits-all approach that involved the use of toxic chemotherapy and invasive surgery. We now know that not all patients and tumors are the same. Tailoring treatments to the individualized biology of each patient’s tumor, has tremendous promise to improve outcomes for people with cancer, while reducing healthcare costs by eliminating unnecessary treatments.

Exact Sciences’ Precision Oncology portfolio of genomic tests provide physicians and patients with personalized insights about the patient’s tumor, allowing them to make treatment decisions with a greater degree of confidence. To date, more than 1.5 million patients in more than 90 countries have relied on our genomic tests to make informed treatment choices for their cancers.1

Exact Sciences Estimates